IPO Report
‘With over $2 billion in cash flow and a healthy 3.7% dividend, this is exactly the type of deal that works in a tough environment,’ says Renaissance Capital
Kenvue, parent to Tylenol among other brands, is going public this week.
Justin Sullivan/Getty Images
Johnson & Johnson’s consumer health company Kenvue is expected to hit the initial public offering market this week and mark the largest deal since late 2021.
Kenvue is parent to a host of household name brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.
“With over $2 billion in cash flow and a healthy 3.7% dividend,…
